Literature DB >> 16231181

Dibenzocyclooctadiene lingnans: a class of novel inhibitors of P-glycoprotein.

Qiangrong Pan1, Qinghua Lu, Kun Zhang, Xun Hu.   

Abstract

PURPOSE: To determine if five dibenzocyclooctadiene lingnans, a class of naturally occurring compounds from Schisandra chinensis (Turcz.) Baill, have the activities to reverse P-glycoprotein (P-gp) mediated multidrug resistance (MDR).
METHODS: The IC(50)s of four MDR cell lines (K562/Adr, MCF-7/Adr, KBv200, and Bcap37/Adr) toward daunorubicin, vincristine, and paclitaxel in the presence or absence of one of the dibenzocyclooctadiene lingnans were determined by a FACscan assay. The intracellular daunorubicin accumulation in the four MDR cell lines was determined by incubation of cells with daunorubicin (2 microg/ml) in the presence or absence of one of the dibenzocyclooctadiene lingnans by a FACscan assay. The interaction of the five dibenzocyclooctadiene lingnans with P-gp was assayed by their inhibition of (3)H-azidopine photoaffinity labeling of P-gp.
RESULTS: Among the five lingnans, while schisandrin A and B, and schisantherin A demonstrated strong and comparable activities to reverse the drug resistance and the intracellular drug accumulation in four MDR cell lines, schisandrol A and B showed very limited activities. The poor activities of schisandrol A and B are possibly caused by the hydroxyl groups on the cyclooctadiene ring, because the activities of the molecules resumed when the hydroxyl group was esterified to form a benzoate. Further studies demonstrated that these compounds physically interacted with P-gp.
CONCLUSION: Schisandrin A and B, and schisantherin A are potent P-gp inhibitor and is of potential for future clinical application.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16231181     DOI: 10.1007/s00280-005-0133-1

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  10 in total

1.  Effects of Schisandra sphenanthera extract on the blood concentration of tacrolimus in renal transplant recipients.

Authors:  Hua-Wen Xin; Qing Li; Xiao-Chun Wu; Yan He; Ai-Rong Yu; Lei Xiong; Ying Xiong
Journal:  Eur J Clin Pharmacol       Date:  2011-06-09       Impact factor: 2.953

2.  Influence of schisantherin A on the pharmacokinetics of lenvatinib in rats and its potential mechanism.

Authors:  Yanjun Cui; Yinling Ma; Ying Li; Haojing Song; Zhanjun Dong
Journal:  J Gastrointest Oncol       Date:  2022-04

3.  Synthesis of unsymmetrical biphenyls as potent cytotoxic agents.

Authors:  Gang Wu; Huan-Fang Guo; Kun Gao; Yi-Nan Liu; Kenneth F Bastow; Susan L Morris-Natschke; Kuo-Hsiung Lee; Lan Xie
Journal:  Bioorg Med Chem Lett       Date:  2008-08-22       Impact factor: 2.823

4.  Curcumin prevents induced drug resistance: a novel function?

Authors:  Dong Xu; Wei Tian; Hong Shen
Journal:  Chin J Cancer Res       Date:  2011-09       Impact factor: 5.087

5.  Schisandrin B prevents doxorubicin-induced chronic cardiotoxicity and enhances its anticancer activity in vivo.

Authors:  Yang Xu; Zhen Liu; Jie Sun; Qiangrong Pan; Feifei Sun; Zhiyu Yan; Xun Hu
Journal:  PLoS One       Date:  2011-12-02       Impact factor: 3.240

6.  Schisantherin A alleviated alcohol-induced liver injury by the regulation of alcohol metabolism and NF-kB pathway.

Authors:  Bin Li; Dongnan Li; Yuehua Wang; Xianjun Meng; Xiyun Sun; Jinlong Tian; Lin Shi; Fengming Ma
Journal:  Exp Anim       Date:  2018-05-25

7.  Effects of Fuzheng Huayu recipe on entecavir pharmacokinetics in normal and dimethylnitrosamine-induced hepatic fibrosis rats.

Authors:  Tao Yang; Tian-Hui Zheng; Qiang Zhao; Wei Liu; Shu-Ping Li; Yan-Yan Tao; Chang-Hong Wang; Cheng-Hai Liu
Journal:  Pharm Biol       Date:  2020-12       Impact factor: 3.503

8.  Anticancer agent shikonin is an incompetent inducer of cancer drug resistance.

Authors:  Hao Wu; Jiansheng Xie; Qiangrong Pan; Beibei Wang; Danqing Hu; Xun Hu
Journal:  PLoS One       Date:  2013-01-03       Impact factor: 3.240

9.  Schisandrin B attenuates cancer invasion and metastasis via inhibiting epithelial-mesenchymal transition.

Authors:  Zhen Liu; Biao Zhang; Kun Liu; Zonghui Ding; Xun Hu
Journal:  PLoS One       Date:  2012-07-25       Impact factor: 3.752

10.  Screening of Natural Compounds as P-Glycoprotein Inhibitors against Multidrug Resistance.

Authors:  Sérgio M Marques; Lucie Šupolíková; Lenka Molčanová; Karel Šmejkal; David Bednar; Iva Slaninová
Journal:  Biomedicines       Date:  2021-03-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.